Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

First NHS patient treated with CSL Behring’s haemophilia B gene therapy Hemgenix

The genetic bleeding disorder affects more than 2,000 people in the UK

- PMLiVE

Mitigating barriers to recruitment and retention in early stage Alzheimer’s trials

By Peter Schueler

People listening to a talk at a conference

A month of insights: Key takeaways from May’s conferences

Explore key insights from some of May’s top healthcare conferences, covering patient engagement, health equity, co-creation, and tech innovation shaping clinical trials.

Cuttsy + Cuttsy

- PMLiVE

Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

- PMLiVE

Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease

Planning is currently underway for a placebo-controlled trial of the candidate

- PMLiVE

GCI Health appoints Aneeb Sharif as EMEA head of policy

Sharif most recently served as head of policy and patient engagement at Syneos Health

- PMLiVE

Communicating with HCPs through AI takes finesse, flexibility and the human touch

While AI’s influence is growing across drug discovery, clinical trials and supply chains, it doesn’t provide that peer-to-peer discussion and sharing of opinions that HCPs want and need

- PMLiVE

New Webinar: The AI-Driven Future of Medical Education for Pharma

Imagine MedEd that thinks, adapts, and delivers unprecedented insights. Better yet, experience if for yourself in our upcoming pharma-exclusive webinar, "Unlocking Brainpower: The AI-Driven Future of Medical Education for Pharma."...

Impetus Digital

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

FDA approves CSL’s Andembry to prevent hereditary angioedema attacks

The genetic disorder affects approximately one in 10,000 to one in 50,000 people worldwide

- PMLiVE

Galderma shares positive long-term data for Nemluvio in prurigo nodularis

The chronic skin disorder is estimated to affect up to 181,000 people in the US

- PMLiVE

Maximising the potential of AI in pharma

The use of AI in pharma can expedite drug development and manufacturing, enabling novel medicines to get to underserved communities more quickly

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links